Shanghai Pharmaceuticals Holding Co., Ltd
601607
Rank in Stocks
#2387
Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding... Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.
Share Price
$2.43
Market Cap
$8.09B
Change (1 day)
-1.16%
Change (1 year)
-5.94%
Country
CN
Trade Shanghai Pharmaceuticals Holding Co., Ltd (601607)
Category
Healthcare
P/E ratio for Shanghai Pharmaceuticals Holding Co., Ltd (601607)
P/E ratio as of 2026 TTM: 0
According to Shanghai Pharmaceuticals Holding Co., Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Shanghai Pharmaceuticals Holding Co., Ltd from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2025 | 11.60 | -32.13% |
| 2024 | 17.09 | 4.19% |
| 2023 | 16.40 | 48.37% |
| 2022 | 11.05 | -0.29% |
| 2021 | 11.09 | -8.65% |
| 2020 | 12.14 | -5.13% |
| 2019 | 12.79 | 7.07% |
| 2018 | 11.95 | -35.65% |
| 2017 | 18.57 | 12.84% |
| 2016 | 16.45 | -11.57% |
| 2015 | 18.61 | 8.74% |
| 2014 | 17.11 | -4.75% |
| 2013 | 17.97 | 23.58% |
| 2012 | 14.54 | 10.80% |
| 2011 | 13.12 | -58.75% |
| 2010 | 31.81 | -80.24% |
| 2009 | 160.94 | 221.88% |
| 2008 | 50.00 | -59.78% |
| 2007 | 124.31 | 208.48% |
| 2006 | 40.30 | 28.12% |
| 2005 | 31.45 | 47.65% |
| 2004 | 21.30 | 15.77% |
| 2003 | 18.40 | -31.84% |
| 2002 | 27.00 | 12.69% |
| 2001 | 23.96 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 26.02 | - |
US
|
|
| - | - |
US
|
|
| 34.08 | - |
US
|
|
| - | - |
US
|
|
| 45.62 | - |
AU
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.